📚 Part of the TILA-278 Regulatory Dossier — Reader's Guide. This article shows the live document; edits to the source appear here automatically.
This is a mock / simulation document, made for a portfolio and for learning. The drug (GLPI-103), the sponsor, the people, and the data are all fictional. It is not a real regulatory submission and has no clinical, legal, or regulatory standing. What is real is the shape of the thing — the document structure, the standards it follows, and the analysis methods; the content inside is illustrative.
What it is. Module 1 — Pediatric Study Plan (PSP/PIP) (TILA-278)
Why it exists. Region-specific administrative content the agency requires in front of the scientific dossier.
How it is produced here. This is a region-specific administrative document, assembled to the local filing and labeling conventions. Its operational and label content is written to stay consistent with the (simulated) clinical data.
Format & governing standard. —
Document ID: M1-PED
Version: 1.0
Change History: 1.0 — Initial issue.
Standard(s): PREA/BPCA; EU 1901/2006
The initial pediatric study plan (US iPSP) and EU paediatric investigation plan for TILA-278 in Ulcerative Colitis (moderate-to-severe): the proposed pediatric development, age-appropriate formulation considerations, planned studies or a request for waiver/deferral with justification. PREA/BPCA; EU Paediatric Regulation 1901/2006.
This plan addresses the paediatric development of TILA-278 (INN tilarudimab; Virtual Biopharma Inc.), a recombinant humanised IgG1 bispecific monoclonal antibody produced in Chinese hamster ovary (CHO) cell culture and administered subcutaneously (SC), for the treatment of moderately-to-severely active ulcerative colitis (UC). TILA-278 delivers a single-molecule dual pharmacology: one arm is an antagonist of TL1A (TNFSF15), dampening TH1/TH17-driven inflammation and intestinal fibrosis; the second arm is an agonist of the IL-22 receptor, driving intestinal epithelial regeneration and mucosal-barrier repair. The proposed adult presentation is a solution for injection in single-use pre-filled syringe and pre-filled pen (autoinjector) at 150 mg and 300 mg per device, with induction dosing at Weeks 0, 2, 4, 8 and 12 followed by maintenance dosing (ATC provisional L04AC).
No comments yet. Be the first to say something!
The plan is submitted concurrently in two regulatory frameworks:
The scope of this plan is limited to the condition "ulcerative colitis". No paediatric development is proposed for indications outside UC.
Occurrence. Ulcerative colitis occurs in the paediatric population. Approximately one in five to one in four patients with inflammatory bowel disease present before 18 years of age, and paediatric-onset UC incidence has been rising over recent decades. Adolescents (12 to < 18 years) account for the majority of paediatric UC; disease is progressively less common in younger children. Very-early-onset IBD (VEO-IBD, typically < 6 years, and most distinctly < 2 years) is a comparatively rare and biologically distinct entity, frequently reflecting monogenic immune-regulatory defects rather than the polygenic, immune-mediated UC seen in adolescents and adults.
Disease characteristics and unmet need. Paediatric UC is frequently more extensive (pancolitis) at diagnosis, more often steroid-dependent or steroid-refractory, and carries a substantial burden on growth, pubertal development, schooling and psychosocial function. The therapeutic armamentarium approved for paediatric UC remains narrower than for adults, and loss of response to available biologics is common. A mechanism combining anti-inflammatory/anti-fibrotic TL1A antagonism with reparative IL-22R agonism is of particular interest in a growing patient in whom durable mucosal healing, avoidance of chronic corticosteroid exposure and reduction of long-term fibrostenotic/colectomy risk are priorities.
Basis for extrapolation. The pathophysiology of adolescent and older-child UC is considered continuous with that of adult UC, including the genetic contribution of the TL1A/TNFSF15 axis and the mucosal biology of IL-22. This supports a partial extrapolation-of-efficacy approach from the adult data for the older paediatric subsets, with confirmation through paediatric pharmacokinetic (PK)/exposure matching and safety characterisation. Extrapolation is not considered appropriate for the < 2-year subset, in which the underlying disease biology (VEO-IBD) differs and the mechanism is unlikely to be relevant.
The adult evidence anchoring the paediatric plan is the pivotal Phase 2b induction study TILA278-201 (randomised, double-blind, placebo-controlled; 1700 screened, 900 randomised 1:1:1 to TILA-278 High / TILA-278 Low / Placebo; full analysis set [FAS] 840 [284 / 283 / 273]). The primary endpoint of clinical remission (modified Mayo score ≤ 2 with no individual subscore > 1) at Week 12 was met with a clear, dose-ordered effect: 37.3% (106/284) High, 16.2% (46/283) Low and 0.7% (2/273) placebo. Supportive key secondary endpoints were consistent, with LS-mean change from baseline in modified Mayo score of −3.36 (High), −2.76 (Low) and −1.00 (placebo) — differences versus placebo of −2.36 and −1.77 — and endoscopic improvement in 48.9%, 27.9% and 6.2%, respectively. The dose-ordered exposure-response relationship established in adults defines the target systemic exposure (that produced by the effective High regimen) to which paediatric dosing will be matched, and provides the efficacy anchor from which adolescent efficacy is partially extrapolated.
Two mechanistic features require explicit paediatric consideration:
As an IgG1, TILA-278 is subject to FcRn-mediated recycling and, in the context of a treated pregnancy, transplacental transfer predominantly in the second and third trimesters; this is relevant to the timing of live-vaccine administration in infants exposed in utero and is reflected in labelling and in pregnancy-outcome surveillance. Elimination is by proteolytic catabolism and target-mediated drug disposition (TMDD) rather than renal or hepatic routes, informing the PK/dosing strategy below.
Development is structured by ICH E11 age subsets and is staged, older-to-younger, to allow accruing PK/safety data to inform dosing in each successively younger subset:
Table PED.1 — Proposed clinical development by age subset
| Age subset (ICH E11) | Proposal | Principal objectives |
|---|---|---|
| Adolescents, 12 to < 18 years | Included (deferred) | Confirm PK and exposure matching to the effective adult regimen; characterise safety, immunogenicity and PD (biomarker/endoscopic); provide efficacy that is partially extrapolated from adults and confirmed by exposure-response |
| Children, 6 to < 12 years | Included (deferred) | Model-informed, weight-band dosing to match adult target exposure; PK, safety, immunogenicity; supportive efficacy |
| Children, 2 to < 6 years | Included (deferred) | Model-informed dosing with exposure matching; PK, safety, immunogenicity; supportive efficacy, contingent on emerging older-subset data and feasibility |
| Birth to < 2 years | Waiver requested | Not proposed for study (see Section 9) |
Extrapolation, modelling and simulation. A quantitative extrapolation framework underpins the plan. A population-PK model incorporating TMDD and allometric (body-weight) scaling, developed from the adult programme and refined with paediatric data as they accrue, will project paediatric doses that reproduce the adult systemic exposure associated with efficacy. Dosing in paediatric subsets is therefore weight-based or weight-band rather than the adult fixed-dose regimen. Adolescent efficacy is partially extrapolated from the adult exposure-response relationship and confirmed through PK/exposure matching plus PD (biomarker and endoscopic) and safety; efficacy in younger subsets relies more heavily on model-informed exposure matching with supportive clinical endpoints. Exposure targets, sampling schemes (sparse/opportunistic where appropriate to minimise paediatric burden) and the pre-specified acceptance criteria for exposure matching will be detailed in the individual paediatric study protocols.
Endpoints and assessments. Paediatric studies will employ disease-activity instruments validated for paediatric UC (including centrally-read endoscopy and paediatric-appropriate composite indices), with growth and pubertal (Tanner-stage) monitoring, and the tiered immunogenicity assessment described below. Where feasible and ethical, PK/PD assessments will be embedded to limit the number of dedicated procedures.
Consistent with the adult programme, anti-drug antibodies (ADA) will be assessed with a validated tiered assay (screening, confirmatory, titre and neutralising-antibody tiers), and the impact of ADA on PK, exposure, efficacy and safety characterised in each paediatric subset — a paediatric immune system may differ in the incidence, persistence and neutralising potential of ADA, and this is a specific object of study. PK will be characterised in the context of TMDD, with body-weight-based dosing to achieve the adult target exposure. Safety monitoring gives explicit attention to: serious and opportunistic infection (including tuberculosis and hepatitis B screening and reactivation, and the paediatric vaccination schedule, with live-vaccine precautions); injection-site reactions and administration tolerability; growth and development; and long-term epithelial/neoplasia vigilance. Long-term safety and durability will be captured through an extension and through the paediatric component of the pharmacovigilance activities described in the Risk Management Plan.
The non-clinical strategy follows ICH S6(R1) for biotechnology-derived products and ICH S11 for the support of paediatric development, integrated with the existing adult package. The cynomolgus monkey is the sole pharmacologically relevant species (human target specificity precludes rodents), and the intended SC route is used.
The paediatric quality strategy uses the same CHO-derived drug substance and the same control principles as the adult product (ICH Q5A(R2) viral safety, Q5C stability of biotechnological products, Q6B specifications), with formal comparability supporting any paediatric presentation. Because paediatric dosing is weight-based, the adult fixed-dose 150 mg and 300 mg devices are not, by themselves, adequate for the smaller/younger subsets. An age-appropriate presentation enabling accurate weight-band or body-weight dosing is proposed (for example a lower-strength pre-filled syringe suitable for graduated volumes), with attention to protein concentration, injectable volume and local tolerability, and to injection-site burden in children. Device human-factors evaluation will address caregiver administration for younger children and self-administration by adolescents. The pre-filled pen (autoinjector) is expected to be appropriate for older adolescents of adult-equivalent weight. The finalised paediatric formulation/presentation and its bridging to the adult product form part of the deferred measures.
A full waiver of the entire paediatric population is not requested, because the condition (UC) occurs in the paediatric population and the mechanism is expected to be relevant to adolescents and older children.
A partial waiver (US) / product-specific waiver (EU) is requested for the subset birth to < 2 years, on the grounds that:
No waiver is requested for the 2 to < 18-year subsets, in which the condition occurs and the mechanism is considered relevant; these subsets are addressed by study, subject to the deferral below.
A deferral of the initiation and/or completion of the paediatric studies in the 2 to < 18-year subsets is requested. The justification is that:
Table PED.2 — Key binding elements / planned measures and indicative milestones (deferred)
| Element | Description | Indicative milestone |
|---|---|---|
| Quality/pharmaceutical measure | Development and comparability of an age-appropriate, weight-band paediatric presentation | Formulation defined and bridging initiated ahead of first paediatric dosing |
| Non-clinical measure | ICH S11 weight-of-evidence assessment of juvenile-animal study need (dedicated study not currently warranted), confirmed with agencies | Assessment finalised prior to paediatric study initiation |
| Clinical study — adolescents (12 to < 18 y) | PK/exposure-matching, safety, immunogenicity, PD and partially-extrapolated efficacy, with open-label long-term extension | Protocol agreed post-approval; initiation and completion per agreed deferred timeline |
| Clinical study — children (6 to < 12 y) | Model-informed weight-band dosing; PK, safety, immunogenicity; supportive efficacy | Initiated after adolescent PK/safety data support dosing |
| Clinical study — children (2 to < 6 y) | Model-informed dosing with exposure matching; PK, safety, immunogenicity; supportive efficacy, contingent on feasibility | Initiated after older-child data; timeline confirmed with agencies |
| Long-term follow-up | Growth/development and long-term safety (infection, epithelial/neoplasia vigilance, immunogenicity persistence) | Continuous through extension and paediatric pharmacovigilance |
Precise study-completion dates and the full set of key binding elements (design, endpoints, sample size, statistical/extrapolation methodology and the exposure-matching acceptance criteria) will be established in the agreed iPSP and in the PDCO opinion/PIP decision, and updated as adult and early paediatric data mature. The staged sequence allows each subset's dosing to be informed by the PK/safety data from the next-older subset.
This plan is intended to support agreement of the US iPSP with the FDA and adoption of a PDCO opinion / EU Decision on the PIP (including the requested waiver for birth to < 2 years and the deferral for 2 to < 18 years). It is consistent with, and cross-references, the adult efficacy and safety summaries (Modules 2.5, 2.7.3 and 2.7.4), the Risk Management Plan (which carries the paediatric development as an agreed PIP with deferral and reflects the long-term paediatric safety commitments), and the Development Safety Update Report. Any subsequent modification to the agreed measures, waiver or deferral will be handled through the applicable iPSP amendment and PIP-modification procedures and captured in the Change History of this document.